Brokers Offer Predictions for AcelRx Pharmaceuticals Inc’s FY2022 Earnings (ACRX)

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) – Jefferies Group issued their FY2022 earnings per share (EPS) estimates for AcelRx Pharmaceuticals in a report released on Tuesday. Jefferies Group analyst M. Andrews anticipates that the specialty pharmaceutical company will earn ($0.25) per share for the year.

ACRX has been the subject of a number of other reports. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of AcelRx Pharmaceuticals in a research report on Friday, October 27th. Zacks Investment Research raised AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a research report on Tuesday, January 16th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company’s stock. AcelRx Pharmaceuticals has a consensus rating of “Hold” and an average price target of $6.21.

Shares of AcelRx Pharmaceuticals (NASDAQ ACRX) traded up $0.02 during trading on Wednesday, reaching $1.73. The company had a trading volume of 238,000 shares, compared to its average volume of 391,073. AcelRx Pharmaceuticals has a twelve month low of $1.55 and a twelve month high of $5.75. The company has a market cap of $88.09, a price-to-earnings ratio of -1.56 and a beta of 2.64. The company has a debt-to-equity ratio of -0.43, a current ratio of 4.78 and a quick ratio of 4.71.

A number of hedge funds have recently added to or reduced their stakes in ACRX. Virtu Financial LLC acquired a new position in AcelRx Pharmaceuticals during the 4th quarter valued at about $120,000. Perennial Advisors LLC acquired a new position in AcelRx Pharmaceuticals during the 3rd quarter valued at about $138,000. Virtu KCG Holdings LLC boosted its stake in AcelRx Pharmaceuticals by 600.9% during the 2nd quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock valued at $255,000 after purchasing an additional 101,742 shares during the last quarter. Geller Family Office Services LLC acquired a new position in AcelRx Pharmaceuticals during the 3rd quarter valued at about $460,000. Finally, Goldman Sachs Group Inc. acquired a new position in AcelRx Pharmaceuticals during the 2nd quarter valued at about $530,000. Institutional investors and hedge funds own 13.61% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Brokers Offer Predictions for AcelRx Pharmaceuticals Inc’s FY2022 Earnings (ACRX)” was published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/14/brokers-offer-predictions-for-acelrx-pharmaceuticals-incs-fy2022-earnings-acrx.html.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Earnings History and Estimates for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply